Kyronyx Biosciences

Kyronyx Biosciences is a Japan-based biotechnology company dedicated to unlocking "undruggable" therapeutic targets through advanced intracellular delivery technology. The company's core innovation is the Kyronyx Intracellular Delivery System (KIDS), a proprietary peptide-based platform designed to transport large molecular cargoes, such as peptides and proteins, across the cell membrane into the cytoplasm and nucleus. This technology specifically addresses the limitations of traditional small molecules and biologics in reaching intracellular protein-protein interactions and transcription factors. Kyronyx is currently leveraging this platform to develop a pipeline of first-in-class oncology therapeutics, with lead programs targeting high-value drivers like MYC and KRAS. By enabling precise delivery to previously inaccessible sites, the company aims to provide transformative treatments for patients with limited therapeutic options. Kyronyx operates out of Tokyo and is backed by prominent Japanese venture capital firms.